Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer

BackgroundInsulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has been reported to exhibit an oncogenic effect as an RNA-binding protein (RBP) by promoting tumor cell proliferation, migration and invasion in several tumor types. However, a pan-cancer analysis of IGF2BP3 is not currently av...

Full description

Bibliographic Details
Main Authors: Pin Chen, Jing Xu, Zihan Cui, Silin Wu, Tao Xie, Xiaobiao Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1071675/full
_version_ 1797943880018034688
author Pin Chen
Jing Xu
Zihan Cui
Zihan Cui
Silin Wu
Tao Xie
Tao Xie
Xiaobiao Zhang
Xiaobiao Zhang
Xiaobiao Zhang
author_facet Pin Chen
Jing Xu
Zihan Cui
Zihan Cui
Silin Wu
Tao Xie
Tao Xie
Xiaobiao Zhang
Xiaobiao Zhang
Xiaobiao Zhang
author_sort Pin Chen
collection DOAJ
description BackgroundInsulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has been reported to exhibit an oncogenic effect as an RNA-binding protein (RBP) by promoting tumor cell proliferation, migration and invasion in several tumor types. However, a pan-cancer analysis of IGF2BP3 is not currently available, and the exact roles of IGF2BP3 in prognosis and immunology in cancer patients remain enigmatic. The main aim of this study was to provide visualization of the systemic prognostic landscape of IGF2BP3 in pan-cancer and to uncover the potential relationship between IGF2BP3 expression in the tumor microenvironment and immune infiltration profile.MethodsRaw data on IGF2BP3 expression were obtained from GTEx, CCLE, TCGA, and HPA data portals. We have investigated the expression patterns, diagnostic and prognostic significance, mutation landscapes, functional analysis, and functional states of IGF2BP3 utilizing multiple databases, including HPA, TISIDB, cBioPortal, GeneMANIA, GESA, and CancerSEA. Moreover, the relationship of IGF2BP3 expression with immune infiltrates, TMB, MSI and immune-related genes was evaluated in pan-cancer. IGF2BP3 with drug sensitivity analysis was performed from the CellMiner database. Furthermore, the expression of IGF2BP3 in different grades of glioma was detected by immunohistochemical staining and western blot.ResultsWe found that IGF2BP3 was ubiquitously highly expressed in pan-cancer and significantly correlated with diagnosis, prognosis, TMB, MSI, and drug sensitivity in various types of cancer. Besides, IGF2BP3 was involved in many cancer pathways and varied in different immune and molecular subtypes of cancers. Additionally, IGF2BP3 is critically associated with genetic markers of immunomodulators in various cancers. Finally, we validated that IGF2BP3 protein expression was significantly higher in glioma than in normal tissue, especially in GBM.ConclusionsIGF2BP3 may be a potential molecular biomarker for diagnosis and prognosis in pan-cancer, especially for glioma. It could become a novel therapeutic target for various cancers.
first_indexed 2024-04-10T20:31:06Z
format Article
id doaj.art-c2fe9e80681c429094fd465b692250ae
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-10T20:31:06Z
publishDate 2023-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-c2fe9e80681c429094fd465b692250ae2023-01-25T06:50:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011410.3389/fimmu.2023.10716751071675Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancerPin Chen0Jing Xu1Zihan Cui2Zihan Cui3Silin Wu4Tao Xie5Tao Xie6Xiaobiao Zhang7Xiaobiao Zhang8Xiaobiao Zhang9Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, ChinaInstitute of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaCancer Center, Shanghai Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaCancer Center, Shanghai Zhongshan Hospital, Fudan University, Shanghai, ChinaDigital Medical Research Center, Fudan University, Shanghai, ChinaBackgroundInsulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has been reported to exhibit an oncogenic effect as an RNA-binding protein (RBP) by promoting tumor cell proliferation, migration and invasion in several tumor types. However, a pan-cancer analysis of IGF2BP3 is not currently available, and the exact roles of IGF2BP3 in prognosis and immunology in cancer patients remain enigmatic. The main aim of this study was to provide visualization of the systemic prognostic landscape of IGF2BP3 in pan-cancer and to uncover the potential relationship between IGF2BP3 expression in the tumor microenvironment and immune infiltration profile.MethodsRaw data on IGF2BP3 expression were obtained from GTEx, CCLE, TCGA, and HPA data portals. We have investigated the expression patterns, diagnostic and prognostic significance, mutation landscapes, functional analysis, and functional states of IGF2BP3 utilizing multiple databases, including HPA, TISIDB, cBioPortal, GeneMANIA, GESA, and CancerSEA. Moreover, the relationship of IGF2BP3 expression with immune infiltrates, TMB, MSI and immune-related genes was evaluated in pan-cancer. IGF2BP3 with drug sensitivity analysis was performed from the CellMiner database. Furthermore, the expression of IGF2BP3 in different grades of glioma was detected by immunohistochemical staining and western blot.ResultsWe found that IGF2BP3 was ubiquitously highly expressed in pan-cancer and significantly correlated with diagnosis, prognosis, TMB, MSI, and drug sensitivity in various types of cancer. Besides, IGF2BP3 was involved in many cancer pathways and varied in different immune and molecular subtypes of cancers. Additionally, IGF2BP3 is critically associated with genetic markers of immunomodulators in various cancers. Finally, we validated that IGF2BP3 protein expression was significantly higher in glioma than in normal tissue, especially in GBM.ConclusionsIGF2BP3 may be a potential molecular biomarker for diagnosis and prognosis in pan-cancer, especially for glioma. It could become a novel therapeutic target for various cancers.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1071675/fullinsulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)pan-cancer analysisgenetic alterationprognosisthe Cancer Genome Atlas (TCGA)immune infiltration
spellingShingle Pin Chen
Jing Xu
Zihan Cui
Zihan Cui
Silin Wu
Tao Xie
Tao Xie
Xiaobiao Zhang
Xiaobiao Zhang
Xiaobiao Zhang
Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
Frontiers in Immunology
insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
pan-cancer analysis
genetic alteration
prognosis
the Cancer Genome Atlas (TCGA)
immune infiltration
title Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
title_full Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
title_fullStr Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
title_full_unstemmed Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
title_short Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
title_sort multi omics analysis of n6 methyladenosine reader igf2bp3 as a promising biomarker in pan cancer
topic insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
pan-cancer analysis
genetic alteration
prognosis
the Cancer Genome Atlas (TCGA)
immune infiltration
url https://www.frontiersin.org/articles/10.3389/fimmu.2023.1071675/full
work_keys_str_mv AT pinchen multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT jingxu multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT zihancui multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT zihancui multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT silinwu multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT taoxie multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT taoxie multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT xiaobiaozhang multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT xiaobiaozhang multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer
AT xiaobiaozhang multiomicsanalysisofn6methyladenosinereaderigf2bp3asapromisingbiomarkerinpancancer